REGULATORY WATCHFDAFTCCOMPLIANCE
The dietary supplement industry in 2025 faced what legal and compliance professionals described as a multi-layer enforcement environment — one where FDA warning letters, FTC oversight, National Advertising Division (NAD) challenges, and retailer compliance requirements were all moving simultaneously, sometimes targeting the same brand behavior from different angles.
For brand operators, the practical consequence is that the compliance landscape is no longer a binary "are we making disease claims?" question. The enforcement picture has become granular enough that social media content linked to shopping carts, implied health claims in influencer language, and "Made in USA" origin language on labels all carry distinct and trackable enforcement risk. Understanding this landscape is not optional for supplement brands operating at any meaningful scale in 2026.
This article is informational analysis of publicly available enforcement trends and should not be construed as legal advice. Supplement brands should work with qualified regulatory counsel for compliance decisions specific to their products and marketing programs.
2025 Enforcement Timeline: What Happened and When
The FDA and FTC issued joint warning letters to 10 companies for illegally marketing dietary supplements with claims to treat, cure, mitigate, or prevent diabetes. This coordinated action signaled that disease-related supplement claims remain a high-priority enforcement area for both agencies, and that joint FDA/FTC action is an established and active tool — not a theoretical risk.
At least five social media-related warning letters were issued in Q2 2025. The pattern: companies whose social media content created a "commercial bridge" between health claims and shopping cart links. The FDA's position is that the linked-cart context transforms educational health content into implied advertising for an unapproved drug use. Companies like Olly and Ryze Superfoods faced scrutiny around marketing and influencer practices during this period.
The FDA issued 14 warning letters in Q3 for noncompliant ophthalmic products — a category signal for brands in adjacent supplement categories. Simultaneously, the FTC sent notification letters to Amazon and Walmart regarding "Made in USA" claims from third-party sellers, expanding the enforcement surface to platform-level liability for origin claims. The FTC's Health Products Compliance Guidance reinforced that all health-related claims must be supported by competent and reliable scientific evidence.
At SupplySide Global, compliance experts formally characterized the 2025 environment as multi-layer enforcement — where FDA, FTC, and NAD actions were often targeting the same company behaviors from overlapping angles. The NAD's challenge process, while voluntary, has become a meaningful enforcement vector for supplement advertising claims that don't rise to FDA/FTC action but still face substantiation challenges from competitors.
Congress enacted significant changes to the federal definition of legal hemp as part of the FY2026 appropriations legislation. Supplement brands with any CBD or hemp-adjacent products needed to reassess their product positioning and labeling against the updated legal framework.
Armstrong Teasdale's December 2025 analysis confirmed that FTC-FDA coordination on supplement and wellness advertising has been explicitly extended to social media and influencer content, and that implied health claims — not just explicit ones — are fully in scope. Enforcement risk is characterized as highest for wellness, functional food, and dietary supplement brands where influencer content blends lifestyle messaging with implied health or efficacy claims.
What Triggered Warning Letters: The Pattern
Across the 2025 enforcement actions, several consistent triggers emerge. Understanding these patterns is the practical first step in assessing your own brand's exposure:
- Disease claims in any format: Explicit or implied claims that a supplement can treat, prevent, cure, or mitigate a disease condition remain the highest-enforcement priority. This includes claims that reference conditions by name in any marketing material — including Amazon listing copy, social media captions, creator content, and email marketing.
- Commercial bridge between health claims and shopping: Content that makes health or efficacy claims and links directly to a purchasing mechanism — whether a TikTok Shop cart, Amazon listing, or website product page — is treated by FDA as advertising for an unapproved use. The presence of the cart link elevates the regulatory risk of content that might otherwise be permissible as educational.
- Unsubstantiated "clinically proven" language: The NAD has actively challenged "clinically proven" claims in supplement advertising. The standard requires that substantiation be calibrated to the strength of the specific claim being made — "clinically proven" implies RCT-level evidence, which most supplement ingredients cannot meet for the specific claims being made.
- Origin claims without component-level substantiation: "Made in USA" claims require substantiation at the component level, not just at final assembly. For supplement brands sourcing active ingredients internationally and manufacturing domestically, this is a significant risk area that many operators have not fully assessed.
- Undisclosed influencer relationships: Any material connection between a brand and a content creator — payment, free product, or affiliate relationship — must be disclosed clearly and conspicuously. "Clearly" and "conspicuously" are defined specifically by FTC guidance and do not include disclosures buried in captions or obscured by other content.
Building a Compliance-First Marketing Operation
The supplement brands that navigated 2025 without enforcement exposure shared a common operational approach: they treated compliance as a pre-launch function, not a post-crisis response. Specifically, this meant pre-clearance of all influencer content before posting, substantiation files that matched the strength of their strongest claims, and documented review processes for Amazon listing copy and social media captions.
For brands building out compliance operations in 2026, the priority areas are: first, audit all existing marketing materials against the commercial bridge standard — identify any content that links health or efficacy language to a purchase mechanism; second, create compliant creator briefs for any influencer or affiliate relationships; third, assess origin claims on packaging and marketing materials against the component-level substantiation standard.
Why Regulatory Intelligence Matters for Brand Strategy
Understanding the regulatory environment isn't only a compliance function — it's a strategic one. Brands that knew in March 2025 that joint FDA/FTC action was targeting diabetes supplement claims had time to assess whether any of their own products or marketing language created exposure, and to adjust before a wider enforcement wave reached their category. Brands tracking Q2 social media warning letter patterns had lead time to brief their influencer partners before enforcement expanded.
Shelf Intelligence tracks FDA warning letters and FTC enforcement actions as part of the weekly Regulatory Watch section — giving subscribers early visibility into enforcement patterns before they become industry news, and time to assess their own exposure while the window is still open.
Get Regulatory Watch every Monday
FDA warning letters, FTC enforcement patterns, import alerts, and compliance updates — synthesized and delivered every Monday before your competitors have started their week.
Subscribe Free